French biopharma major Ipsen expands direct operations to MEA with headquarters in the UAE

• Expansion to the MEA highlights Ipsen’s vision of creating value by serving patients with high unmet medical needs across oncology, rare diseases and neuroscience.
• His Excellency Dr Amin Hussain Al Amiri, Assistant Undersecretary of Health Regulations Sector at the UAE Ministry of Health and Prevention (MoHAP), and Her Excellency Raja Rabia, Consul General of France to Dubai and Northern Emirates officiated the ceremony. 

Dubai (UAE):- Ipsen (Euronext: IPN; ADR: IPSEY), inaugurated its first regional office in the Middle East and Africa (MEA), headquartered in Dubai, to kickstart direct operations and bring innovative treatments to serve unmet medical needs covering oncology, rare diseases and neuroscience in the region.

The opening of Ipsen’s regional headquarters in the Al Jalila Foundation Building at Dubai Healthcare City was attended by His Excellency Dr Amin Hussain Al Amiri, Assistant Undersecretary of Health Regulations Sector at the UAE Ministry of Health and Prevention (MoHAP), Her Excellency Raja Rabia, Consul General of France to Dubai and Northern Emirates, Dr Abdulkareem Sultan Al Olama, CEO of Al Jalila Foundation, Professor Humaid Al Shamsi, President of the Emirates Oncology Society, representatives of the medical community, and Ipsen leaders.

His Excellency Dr Amin Hussain Al Amiri said,“The UAE has emerged as a global pharmaceutical hub led by an exceptional healthcare and business infrastructure, and a strong legislative environment that supports innovative and international-standard healthcare enterprises. Ipsen’s commitment to investing in the UAE and the region, and its decision to open its regional headquarters here is a welcome step that further underlines our nation’s rich legacy of facilitating the regional expansion of multinational firms. We look forward to path-breaking therapies by Ipsen that will help the healthcare community further secure the wellbeing of our communities.”

Her Excellency Raja Rabia, Consul General of France to Dubai and Northern Emirates said,“The United Arab Emirates and France enjoy a strong and long-standing relationship covering culture, business, education, healthcare and more. Over the years, French companies have contributed to the economy and gained from the opportunities offered by the country both at a national level and to expand to regional markets. We congratulate Ipsen on the opening of their new regional headquarters in the UAE and look forward to the positive impact this creates on the lives of patients as we continue to strengthen the friendship between our nations and build on the strong bilateral relations.” 

Dr Abdulkareem Sultan Al Olama, CEO of Al Jalila Foundation, said: “Ipsen’s decision to open their first regional office in the Middle East and Africa (MEA) in Dubai is testament to the growing healthcare industry in the UAE with the pharmaceutical sector being a major player. In Al Jalila Foundation’s mission to create a medical research innovation hub for the advancement of science, we are extremely proud that Ipsen chose our building as a base for their operations to serve patients in the region.”

Vice President of Middle East, Africa and Maghreb for Ipsen, Matthieu Savarzeix said, “As a French biopharmaceutical company with over 90 years of heritage and a global presence in advancing R&D programs, we have continuously focused on creating exceptional value to the local communities we serve. We are dedicated to improving patients’lives and health outcomes, and consistently focus on introducing innovative treatments and breakthrough medicines that help enhance the quality of life” 

Middle East and Africa Specialty Care Operations Head for Ipsen, Khaled Elrefae added, “The opening of our new office in Dubai is a milestone for our company. We look forward to building value through our global innovation in oncology, rare diseases and neuroscience, as we strive to contribute to the health and well-being of the people of the UAE, and the region, especially at a time when healthcare is top priority.”

The pharmaceutical industry has been a key focus area for the UAE over the past decade, with the government implementing strategic and long-term plans to develop and grow the market. Multinational pharmaceutical companies are leveraging the country’s robust infrastructure, economic incentives and attractiveness to top talent to manage vast regions. Ipsen’s regional office and headquarters will help in faster access to innovative treatments for patients with unmet medical needs.

Addressing life-threatening and underserved diseases through transformative medicines, Ipsen’s areas of expertise include Neuroendocrine tumors which is the second most prevalent gastrointestinal neoplasm after colorectal cancer[1]; prostate cancer, breast cancer, spasticity, and renal and hepatocellular cell carcinoma among others.

In 2020, Ipsen Group reported net sales which exceeded 2.5 billion Euros, representing 3% growth in sales. The company continued to increase R&D investments reaching 15.6% of net sales and has also made significant strides in building a rare disease franchise for the next decade.

-Ends-

Ipsen

Ipsen is a global, mid-sized biopharmaceutical company focused on transformative medicines in Oncology, Neuroscience and Rare Disease; it also has a well-established Consumer Healthcare business. With Total Sales of over €2.5bn in FY 2020, Ipsen sells more than 20 medicines in over 115 countries, with a direct commercial presence in more than 30 countries. The Company’s research and development efforts are focused on its innovative and differentiated technological platforms located in the heart of leading biotechnological and life-science hubs: Paris-Saclay, France; Oxford, U.K.; Cambridge, U.S.; Shanghai, China. Ipsen has c.5,700 colleagues worldwide and is listed in Paris (Euronext: IPN) and in the U.S. through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY). For more information, visit www.ipsen.com  

Forward-looking statements

The forward-looking statements, objectives and targets contained herein are based on the Group’s management strategy, current views and assumptions. Such statements involve known and unknown risks and uncertainties that may cause actual results, performance or events to differ materially from those anticipated herein. All of the above risks could affect the Group’s future ability to achieve its financial targets, which were set assuming reasonable macroeconomic conditions based on the information available today. Use of the words "believes", "anticipates" and "expects" and similar expressions are intended to identify forward-looking statements, including the Group’s expectations regarding future events, including regulatory filings and determinations. Moreover, the targets described in this document were prepared without taking into account external growth assumptions and potential future acquisitions, which may alter these parameters. These objectives are based on data and assumptions regarded as reasonable by the Group. These targets depend on conditions or facts likely to happen in the future, and not exclusively on historical data. Actual results may depart significantly from these targets given the occurrence of certain risks and uncertainties, notably the fact that a promising product in early development phase or clinical trial may end up never being launched on the market or reaching its commercial targets, notably for regulatory or competition reasons. The Group must face or might face competition from generic products that might translate into a loss of market share. Furthermore, the Research and Development process involves several stages each of which involves the substantial risk that the Group may fail to achieve its objectives and be forced to abandon its efforts with regards to a product in which it has invested significant sums. Therefore, the Group cannot be certain that favorable results obtained during pre-clinical trials will be confirmed subsequently during clinical trials, or that the results of clinical trials will be sufficient to demonstrate the safe and effective nature of the product concerned. There can be no guarantees a product will receive the necessary regulatory approvals or that the product will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Other risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the Group's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the Group’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions. The Group also depends on third parties to develop and market some of its products which could potentially generate substantial royalties; these partners could behave in such ways which could cause damage to the Group’s activities and financial results. The Group cannot be certain that its partners will fulfil their obligations. It might be unable to obtain any benefit from those agreements. A default by any of the Group’s partners could generate lower revenues than expected. Such situations could have a negative impact on the Group’s business, financial position or performance. The Group expressly disclaims any obligation or undertaking to update or revise any forward-looking statements, targets or estimates contained in this press release to reflect any change in events, conditions, assumptions or circumstances on which any such statements are based, unless so required by applicable law. The Group’s business is subject to the risk factors outlined in its registration documents filed with the French Autorité des Marchés Financiers. The risks and uncertainties set out are not exhaustive and the reader is advised to refer to the Group’s 2020 Registration Document, available on ipsen.com.

For more information, contact:
Ipsen
Islam Saleh
Marketing Director, Oncology and Sepciality Care – META
E: islam.saleh@ipsen.com  

GCI Health Middle East
Stephanie Tasrini
Account Director
E: stephanie.tasrini@gcihealth.com 

© Press Release 2021